Overview

Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate if renal impairment will have an impact on the pharmacokinetics of nalmefene
Phase:
Phase 1
Details
Lead Sponsor:
H. Lundbeck A/S
Treatments:
Nalmefene
Naltrexone